Association between abciximab and length of stay in intensive care for patients undergoing percutaneous coronary intervention: A 2-stage econometric model in a naturalistic setting

PharmacoEconomics

Volumn 18, Issue 6, 2000, Pages 581-589

  Lage, M J ^a   Barber, B L ^b   Bala, M ^c   McCollam, P L ^b   Ball, D E ^b  

^a MIAMI UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG CHOICE; ECONOMIC ASPECT; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH STATUS; HIGH RISK PATIENT; HOSPITAL; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL MODEL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

EID: 0034502596     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018060-00005     Document Type: Article

References (39)

1. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary sapheneous vein grafts
2. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
3. An overview of the results of the EPIC trial
4. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
7. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective
8. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
9. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
10. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications
11. The development of a method for comparative costing of individual intensive care units
12. Federal and nationwide intensive care units and healthcare costs: 1986-1992
13. Analyzing intensive care unit length of stay data: Problems and possible solutions
14. Variations in mortality and length of stay in intensive care units
15. Improving intensive care: Observations based on organizational case studies in nine intensive care units: A prospective, multicenter study
16. Generalized models with selectivity
17. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain
18. Length of hospital stay after acute myocardial infarction in the myocardial infarction triage and intervention (MITI) project registry
19. Sample selection bias as a specification error
20. Issues in the analysis of selectivity bias
21. Selecting a patient characteristic index for the prediction of medical outcomes using administrative claims data
22. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states
23. Differences in the use of procedures between women and men hospitalized for coronary heart disease
24. Sex differences in the management of coronary artery disease
25. Long-term implications of racial differences in the use of revascularization procedures (the myocardial infarction triage and intervention registry)
26. Racial variation in cardiac procedure use and survival following myocardial infarction in the Department of Veterans Affairs
27. Racial differences in the use of revascularization procedures after coronary angioplasty
28. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts
29. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
30. Shorter hospital stays for angioplasty patients who receive abciximab
31. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study
32. Abciximab therapy in percutaneous intervention: Economic issues in the United States
33. The use of APACHE III to evaluate ICU length of stay, resource use, and mortality after coronary artery by-pass surgery
34. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality?: Analysis using instrumental variables
35. Cost and resource utilization in intensive care
36. Costs and effects of c7E3 in high risk PTCA patients: An indirect analysis for the Netherlands
37. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization